InvestorsHub Logo
Followers 8
Posts 2018
Boards Moderated 0
Alias Born 07/19/2006

Re: gr8db8 post# 561

Wednesday, 01/11/2017 12:51:16 AM

Wednesday, January 11, 2017 12:51:16 AM

Post# of 2099
If you look at the phase II trial, there were two CR's out of 24 patients or about 10 percent. If you look at the historical trials in rGBM with Avastin, I've found a single CR out of well over 150 patients in total and I'm not even sure if it was durable. If they can attain a similar(or slightly better)rate in the phase III trial, it would be stunning. Bottom line, Avastin does not produce a CR in rGBM(durable or fleeting).

I found the update by searching VB-111 on Facebook including a before MRI with a 3.8cm tumor, then 1cm, then no tumor over six months of treatment(3VB-111 infusions). I didn't want to link to this here on a public forum for obvious reasons. Yes, 1 patient achieving an ongoing CR does not equal success, but something happened(in phase II and III)that does not happen with Avastin. The real story will be does, on aggregate, VB-111 produce better tumor control compared to avastin? Not just more PR and CR's, but also slower tumor growth and, also importantly, survival after progression, i.e. slower tumor growth after patients "fail" VB-111/Avastin.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News